X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x - -897.3 - View Chart
P/BV x 6.4 0.3 2,426.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
VENUS REMEDIES
Mar-16
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,589218 728.9%   
Low Rs1,23282 1,500.6%   
Sales per share (Unadj.) Rs417.5365.6 114.2%  
Earnings per share (Unadj.) Rs56.31.5 3,788.3%  
Cash flow per share (Unadj.) Rs64.737.9 170.6%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9382.5 76.6%  
Shares outstanding (eoy) m119.5711.44 1,045.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 823.3%   
Avg P/E ratio x25.1101.0 24.8%  
P/CF ratio (eoy) x21.84.0 550.9%  
Price / Book Value ratio x4.80.4 1,227.5%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,717 9,825.0%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m9,171324 2,827.2%   
Avg. sales/employee Rs ThNM4,100.7-  
Avg. wages/employee Rs ThNM318.0-  
Avg. net profit/employee Rs ThNM16.7-  
INCOME DATA
Net Sales Rs m49,9154,183 1,193.4%  
Other income Rs m1,64520 8,184.6%   
Total revenues Rs m51,5614,203 1,226.8%   
Gross profit Rs m8,482812 1,045.1%  
Depreciation Rs m1,006417 241.3%   
Interest Rs m671380 176.6%   
Profit before tax Rs m8,45135 24,076.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60618 8,872.9%   
Profit after tax Rs m6,73117 39,595.3%  
Gross profit margin %17.019.4 87.6%  
Effective tax rate %19.051.6 36.9%   
Net profit margin %13.50.4 3,317.9%  
BALANCE SHEET DATA
Current assets Rs m27,0622,771 976.7%   
Current liabilities Rs m15,3241,931 793.4%   
Net working cap to sales %23.520.1 117.2%  
Current ratio x1.81.4 123.1%  
Inventory Days Days67125 53.2%  
Debtors Days Days4154 76.8%  
Net fixed assets Rs m12,6105,328 236.6%   
Share capital Rs m239114 209.0%   
"Free" reserves Rs m34,4904,177 825.7%   
Net worth Rs m35,0274,376 800.4%   
Long term debt Rs m1,2121,911 63.4%   
Total assets Rs m54,3878,428 645.3%  
Interest coverage x13.61.1 1,245.1%   
Debt to equity ratio x00.4 7.9%  
Sales to assets ratio x0.90.5 184.9%   
Return on assets %13.64.7 289.1%  
Return on equity %19.20.4 4,947.1%  
Return on capital %24.96.6 376.6%  
Exports to sales %12.90-   
Imports to sales %3.120.5 15.0%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540858 179.5%   
Fx inflow Rs m6,5630-   
Fx outflow Rs m3,012858 350.9%   
Net fx Rs m3,552-858 -413.8%   
CASH FLOW
From Operations Rs m7,259469 1,548.3%  
From Investments Rs m1,86429 6,384.2%  
From Financial Activity Rs m-9,273-464 2,000.6%  
Net Cashflow Rs m-15035 -434.8%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Remains Positive; PSU & Power Stocks in Demand(01:30 pm)

After opening the day on a positive note, the Indian share markets have continued the momentum and are presently trading above the dotted line ahead of October F&O expiry and Infosys results.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Rs 71 Trillion Business Could Make or Break (Your) Wealth in the Next Decade(The 5 Minute Wrapup)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

The Delusional Optimism of India's Real Estate Companies(Vivek Kaul's Diary)

Oct 16, 2017

This is a sector which hasn't gone anywhere in nearly six years, but those who run it continue to remain optimistic.

How Many Shares Should One Buy?(Daily Profit Hunter)

Oct 18, 2017

How much to buy is the biggest challenge after deciding what to buy. Here's your solution.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2018
Get our special report, Multibagger Stocks Guide (2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 24, 2017 02:43 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS